A Study of AZD4901 in Females With Polycystic Ovary Syndrome
A Study of AZD4901 in Females With Polycystic Ovary Syndrome
To assess the effects of AZD4901 when given in multiple doses to females with Polycystic
 Ovary Syndrome
Inclusion Criteria:

 Female patients between the ages of 18 to 45 years (inclusive). Suitable veins for
 cannulation or repeated venipuncture. Body mass index (BMI) between 18 and 40 kg/m2
 (inclusive). A diagnosis of polycystic ovary disease. Amenorrhea or oligomenorrhea (defined
 as ≤ 6 menses per year). Negative serum pregnancy test at screening. Negative urine
 pregnancy test before randomisation. Not be breast-feeding. Not have been pregnant within
 the 6 months prior to screening.

 Exclusion Criteria:

 Perimenopausal or reached natural menopause, defined as FSH > 10 IU/L. Menstruated within
 the month prior to the baseline visit. Hysterectomy or bilateral oophorectomy or both.
 Clinically relevant disease and abnormalities (past or present), and in particular causes
 of abnormal vaginal bleeding.

 Withdrawals from oral contraceptives if their LH levels are below 3 IU/L when retested
 within 7 ± 1 days of the baseline visit.